Table 2.
Standardized Incidence Ratios (SIRs) and 95% confidence intervals (CI) adjusted for age, year, race, and sex
| Private Applicators | Commercial Applicators | Spouses | |||||||
|---|---|---|---|---|---|---|---|---|---|
| N | SIR | CI | N | SIR | CI | N | SIR | CI | |
| All Sites | 8256 | 0.91 | (0.89, 0.93) | 444 | 0.83 | (0.76, 0.92) | 3720 | 0.89 | (0.86, 0.92) |
| Oral Cavity and Pharynx | 198 | 0.69 | (0.60, 0.80) | 10 | 0.50 | (0.24, 0.92) | 44 | 0.72 | (0.52, 0.96) |
| Lip | 63 | 2.22 | (1.71, 2.84) | 4 | – | – | 7 | 1.76 | (0.71, 3.63) |
| Tongue | 35 | 0.46 | (0.32, 0.64) | 2 | – | – | 15 | 0.89 | (0.50, 1.47) |
| Tonsil | 27 | 0.47 | (0.31, 0.68) | 1 | – | – | 3 | – | – |
| Digestive System | 1407 | 0.87 | (0.82, 0.91) | 84 | 0.83 | (0.66, 1.03) | 540 | 0.81 | (0.74, 0.88) |
| Esophagus | 102 | 0.71 | (0.58, 0.86) | 13 | 1.29 | (0.69, 2.21) | 9 | 0.51 | (0.23, 0.97) |
| Stomach | 114 | 0.91 | (0.75, 1.10) | 2 | – | – | 28 | 0.78 | (0.52, 1.12) |
| Small Intestine | 44 | 1.13 | (0.82, 1.52) | 4 | – | – | 11 | 0.61 | (0.30, 1.09) |
| Colon and Rectum | 842 | 0.95 | (0.89, 1.02) | 49 | 0.89 | (0.66, 1.18) | 346 | 0.87 | (0.78, 0.96) |
| Proximal Colon | 310 | 0.94 | (0.84, 1.05) | 17 | 0.89 | (0.52, 1.42) | 169 | 0.93 | (0.80, 1.09) |
| Distal Colon | 226 | 0.99 | (0.87, 1.13) | 13 | 0.93 | (0.49, 1.58) | 84 | 0.91 | (0.73, 1.13) |
| Rectum and Rectosigmoid Junction | 260 | 0.95 | (0.84, 1.08) | 17 | 0.89 | (0.52, 1.42) | 74 | 0.75 | (0.59, 0.94) |
| Anus, Anal Canal and Anorectum | 8 | 0.44 | (0.19, 0.87) | 1 | – | – | 6 | 0.30 | (0.11, 0.66) |
| Liver and Intrahepatic Bile Duct | 78 | 0.56 | (0.45, 0.70) | 4 | – | – | 21 | 0.71 | (0.44, 1.08) |
| Pancreas | 183 | 0.83 | (0.72, 0.96) | 10 | 0.76 | (0.37, 1.41) | 71 | 0.69 | (0.54, 0.87) |
| Peritoneum, Omentum and Mesentery | 1 | -- | – | 0 | – | – | 21 | 1.80 | (1.11, 2.75) |
| Respiratory System | 881 | 0.51 | (0.47, 0.54) | 56 | 0.65 | (0.49, 0.85) | 259 | 0.40 | (0.36, 0.46) |
| Larynx | 66 | 0.48 | (0.37, 0.62) | 4 | – | – | 5 | 0.26 | (0.09, 0.62) |
| Lung and Bronchus | 807 | 0.51 | (0.48, 0.55) | 51 | 0.67 | (0.50, 0.88) | 252 | 0.41 | (0.36, 0.46) |
| Small-Cell Carcinoma | 138 | 0.58 | (0.48, 0.68) | 10 | 0.81 | (0.39, 1.49) | 39 | 0.34 | (0.24, 0.46) |
| Non-Small Cell Carcinoma | 633 | 0.51 | (0.47, 0.55) | 40 | 0.67 | (0.48, 0.91) | 199 | 0.44 | (0.38, 0.50) |
| Squamous Cell Carcinoma | 209 | 0.51 | (0.45, 0.59) | 15 | 0.81 | (0.45, 1.34) | 42 | 0.39 | (0.28, 0.53) |
| Adenocarcinoma | 238 | 0.54 | (0.47, 0.61) | 16 | 0.62 | (0.35, 1.01) | 106 | 0.51 | (0.42, 0.61) |
| Large-Cell Carcinoma | 68 | 0.39 | (0.30, 0.50) | 3 | – | – | 9 | 0.17 | (0.08, 0.31) |
| Melanoma of the Skin | 393 | 1.01 | (0.91, 1.12) | 26 | 1.03 | (0.67, 1.51) | 177 | 1.21 | (1.04, 1.40) |
| Breast | 63 | 0.86 | (0.66, 1.10) | 2 | – | – | 1389 | 1.05 | (0.99, 1.11) |
| Female Genital System | 21 | 0.95 | (0.59, 1.45) | 2 | – | – | 498 | 0.97 | (0.88, 1.05) |
| Cervix Uteri | 3 | -- | – | 0 | – | – | 29 | 0.50 | (0.34, 0.72) |
| Corpus and Uterus | 6 | 0.49 | (0.18, 1.08) | 1 | – | – | 323 | 1.13 | (1.01, 1.27) |
| Ovary and Fallopian Tube | 11 | 1.80 | (0.90, 3.22) | 0 | – | – | 122 | 0.87 | (0.72, 1.04) |
| Male Genital System | 3228 | 1.15 | (1.11, 1.19) | 157 | 1.03 | (0.87, 1.20) | 11 | 0.89 | (0.44, 1.59) |
| Prostate | 3169 | 1.15 | (1.11, 1.19) | 149 | 1.02 | (0.86, 1.19) | 11 | 0.90 | (0.45, 1.61) |
| Testis | 45 | 1.31 | (0.96, 1.75) | 7 | 1.28 | (0.51, 2.65) | 0 | – | – |
| Urinary System | 740 | 0.80 | (0.74, 0.85) | 39 | 0.72 | (0.51, 0.98) | 154 | 0.76 | (0.64, 0.88) |
| Urinary Bladder | 411 | 0.70 | (0.63, 0.77) | 26 | 0.83 | (0.54, 1.22) | 60 | 0.64 | (0.49, 0.82) |
| Kidney and Renal Pelvis | 314 | 0.96 | (0.86, 1.07) | 12 | 0.53 | (0.28, 0.93) | 92 | 0.88 | (0.71, 1.07) |
| Brain | 87 | 0.79 | (0.63, 0.97) | 6 | 0.72 | (0.26, 1.57) | 49 | 1.00 | (0.74, 1.32) |
| Endocrine System | 92 | 1.17 | (0.95, 1.44) | 12 | 1.58 | (0.82, 2.76) | 123 | 1.20 | (1.00, 1.44) |
| Thyroid | 82 | 1.15 | (0.92, 1.43) | 11 | 1.55 | (0.77, 2.77) | 118 | 1.20 | (0.99, 1.44) |
| Papillary Carcinoma | 66 | 1.19 | (0.92, 1.52) | 8 | 1.37 | (0.59, 2.70) | 110 | 1.30 | (1.07, 1.57) |
| All Lymphohematopoietic | 830 | 1.07 | (0.99, 1.14) | 40 | 0.76 | (0.54, 1.04) | 330 | 1.00 | (0.89, 1.11) |
| Lymphoid Malignancies | 700 | 1.08 | (1.00, 1.16) | 36 | 0.82 | (0.57, 1.13) | 290 | 1.04 | (0.92, 1.16) |
| Hodgkin Lymphoma | 27 | 0.99 | (0.65, 1.44) | 2 | – | – | 10 | 0.87 | (0.42, 1.60) |
| B-Cell Lymphoma | 624 | 1.12 | (1.03, 1.21) | 32 | 0.85 | (0.58, 1.20) | 265 | 1.09 | (0.96, 1.23) |
| Chronic Lymphocytic Leukemia | 166 | 1.17 | (1.00, 1.36) | 9 | 0.93 | (0.42, 1.76) | 43 | 0.88 | (0.63, 1.18) |
| Diffuse Large B-Cell Lymphoma | 145 | 1.16 | (0.98, 1.37) | 5 | 0.56 | (0.18, 1.32) | 70 | 1.23 | (0.96, 1.55) |
| Marginal Zone Lymphoma | 16 | 0.61 | (0.35, 0.99) | 2 | – | – | 25 | 1.46 | (0.95, 2.16) |
| Follicular Lymphoma | 81 | 1.14 | (0.91, 1.42) | 7 | 1.25 | (0.50, 2.58) | 54 | 1.33 | (1.00, 1.74) |
| Multiple Myeloma | 146 | 1.18 | (0.99, 1.38) | 5 | 0.71 | (0.23, 1.67) | 57 | 1.04 | (0.79, 1.35) |
| T-Cell Lymphoma | 27 | 0.89 | (0.58, 1.29) | 1 | – | – | 8 | 0.69 | (0.30, 1.36) |
| Leukemia | 145 | 1.10 | (0.93, 1.30) | 7 | 0.82 | (0.33, 1.7) | 45 | 0.88 | (0.65, 1.18) |
| Lymphocytic Leukemia | 14 | 0.77 | (0.42, 1.30) | 2 | – | – | 5 | 0.81 | (0.26, 1.88) |
| Myeloid and Monocytic Leukemia | 115 | 1.12 | (0.92, 1.34) | 4 | – | – | 38 | 0.94 | (0.66, 1.29) |
| Acute Myeloid/Monocytic Leukemia | 86 | 1.29 | (1.03, 1.59) | 3 | – | – | 33 | 1.21 | (0.83, 1.69) |
| Chronic Myeloid Leukemia | 25 | 0.76 | (0.49, 1.13) | 1 | – | – | 5 | 0.41 | (0.13, 0.95) |
| Mesothelioma | 21 | 0.85 | (0.53, 1.30) | 0 | – | – | 4 | – | – |
| Myelodysplastic/Myeloproliferati ve Neoplasm1 | 87 | 0.81 | (0.65, 1.00) | 0 | – | – | 38 | 0.78 | (0.55, 1.07) |
| Myelodysplastic Syndrome | 48 | 0.84 | (0.62, 1.12) | 0 | – | – | 19 | 0.95 | (0.57, 1.48) |
| Myeloproliferative Neoplasm | 36 | 0.75 | (0.53, 1.04) | 0 | – | – | 16 | 0.59 | (0.34, 0.95) |
1
Analyses restricted to 2001-on when these tumors became reportable to central cancer registries